Oruka Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
ORKA$104.56+1.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)
| September 30, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $91,253 | $61,575 |
| Marketable securities, current | 257,902 | 314,073 |
| Prepaid expenses and other current assets | 6,008 | 1,221 |
| Total current assets | 355,163 | 376,869 |
| Marketable securities, long-term | 151,763 | 18,069 |
| Property and equipment, net | 253 | 162 |
| Operating lease right-of-use assets | 1,969 | 876 |
| Other non-current assets | 103 | 43 |
| Total assets | $509,251 | $396,019 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $2,208 | $3,462 |
| Accrued expenses and other current liabilities | 8,648 | 3,346 |
| Operating lease liability, current | 419 | 213 |
| Related party common stock warrant liability | 9,684 | — |
| Related party accounts payable and other current liabilities | 8 | 6,022 |
| Total current liabilities | 20,967 | 13,043 |
| Operating lease liability, non-current | 1,493 | 755 |
| Total liabilities | 22,460 | 13,798 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ equity: | ||
| Series B non-voting convertible preferred stock, $0.001 par value; 251,504 shares authorized as of September 30, 2025 and December 31, 2024; 137,138 shares issued and outstanding as of September 30, 2025 and December 31, 2024 | 2,931 | 2,931 |
| Common stock, $0.001 par value; 545,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 48,384,150 and 37,440,510 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | 48 | 37 |
| Additional paid-in capital | 643,201 | 463,018 |
| Accumulated other comprehensive income (loss) | 185 | (41) |
| Accumulated deficit | (159,574) | (83,724) |
| Total stockholders’ equity | 486,791 | 382,221 |
| Total liabilities and stockholders’ equity | $509,251 | $396,019 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.